Ul­tragenyx to spin off com­pa­ny to de­vel­op ‘high risk, high re­turn’ gene ther­a­py for Alzheimer’s dis­ease

Ul­tragenyx plans to spin off a com­pa­ny ded­i­cat­ed to de­vel­op­ing a nov­el gene ther­a­py for Alzheimer’s dis­ease that makes use of a lyso­so­mal en­zyme, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.